Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Regains Compliance With Rules for Nasdaq Listing

NEW YORK ─ Molecular diagnostic company Genetic Technologies said on Tuesday it received notification from the Nasdaq Stock Market that it now meets a minimum stockholders equity requirement for continued listing of its American Depositary Shares (ADSs) on the Nasdaq.

Melbourne, Australia-based Genetic Technologies, a developer of genetic risk assessment tests, noted that since April 2020, it had raised a total of about $16.4 million through offerings of its American Depositary Shares and it had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with Nasdaq's listing rule.

The firm, a developer of predictive testing and assessment tools for cancers, said in March it had received a notice that it is out of compliance with the Nasdaq's continued listing requirements.

In July, the firm announced it inked definitive agreements to sell $5.1 million worth of ADSs to institutional investors.

The firm had also lost and regained compliance with Nasdaq listing requirements in 2019 and 2018.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.